- Agreement will facilitate clinical trial translations in China 

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is 
collaborating with Beijing Advaccine Biotechnology Co. to advance the 
development in China of INO-4800, Inovio's vaccine against the recently emerged 
strain of coronavirus (2019-nCoV) that has killed numerous people and infected 
thousands more in China to date. Inovio recently announced that it is 
developing INO-4800 through Phase 1 human testing in the U.S. to evaluate 
safety and immunogenicity with the support of an initial grant up to $9 million 
from the Coalition for Epidemic Preparedness Innovations (CEPI).

Inovio plans to rapidly develop INO-4800 against the new coronavirus and has 
already started preclinical testing and preparations for clinical product 
manufacturing. The goal of this collaboration is to leverage Advaccine's 
expertise to run a Phase 1 trial in China in parallel with Inovio's clinical 
development efforts in the U.S. Inovio and Advaccine will also work together to 
attract additional grant funding and further collaborations with larger vaccine 
companies in China to increase the speed of future testing of INO-4800.

Dr. J. Joseph Kim, Inovio's President & CEO, said, "Our collaboration with 
Beijing Advaccine and its Founder, Emeritus Professor Bin Wang from the 
prestigious Fudan University and China's premier DNA vaccine expert, will 
tremendously accelerate our coronavirus vaccine INO-4800 development in China 
because of its expertise and experience with regulatory authorities and 
clinical trial management. This collaboration allows us to enter China and 
deliver our vaccine into the areas where they need it most as soon as possible. 
Our shared goal is to utilize both company's expertise in developing vaccines 
for emerging infectious diseases and hopefully achieve an accelerated 
regulatory approval for INO-4800."

Inovio's participation in this developing effort is based on the ideal 
suitability of its DNA medicine platform to rapidly develop vaccines against 
emerging viruses with pandemic potential, proven vaccine development 
capabilities, and a strong track record of rapidly generating promising 
countermeasures against previous pandemic threats. Inovio was the first to 
advance its vaccine (INO-4700) against MERS-CoV, a related coronavirus, into 
evaluation in humans. Inovio is currently preparing to initiate a Phase 2 trial 
for INO-4700 in the Middle East where most MERS viral outbreaks have occurred. 
Those efforts are supported by CEPI funding and partnership.

In a recently published paper in Lancet Infectious Diseases, Inovio's Phase 1 
study of INO-4700, its MERS-CoV vaccine, demonstrated it was well-tolerated and 
furthermore induced high levels of antibody responses in approximately 95% of 
subjects, while also generating broad-based T cell responses in nearly 90% of 
study participants. Durable antibody responses to INO-4700 were also maintained 
through 60 weeks following dosing.

Inovio's other collaborators in this coronavirus vaccine development include 
the Wistar Institute and VGXI, a fully owned subsidiary of GeneOne Life Science 
(KSE: 011000).

About Inovio Pharmaceuticals, Inc.

Inovio is a biotechnology company focused on rapidly bringing to market 
precisely designed DNA medicines to treat, cure and/or protect people from 
diseases associated with HPV, cancer, and infectious diseases. Inovio is the 
first and only company to have clinically demonstrated that a DNA medicine can 
be delivered directly into cells in the body via a proprietary smart device to 
safely produce a robust immune response to destroy and clear high-risk HPV 16 
and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer 
and 69% of vulvar cancer. In addition to HPV, Inovio's optimized plasmid design 
and delivery technology has been demonstrated to consistently activate robust 
and fully functional T cell and antibody responses against targeted cancers and 
pathogens. Inovio's most advanced clinical program, VGX-3100, is in Phase 3 
development for the treatment of HPV-related cervical pre-cancer. Also in 
development are Phase 2 immuno-oncology programs targeting HPV-related cancers 
and GBM, as well as externally funded platform development programs in Zika, 
MERS, Lassa, and HIV. Partners and collaborators include ApolloBio Corporation, 
AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic 
Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, 
GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense 
Consortium (MCDC), National Cancer Institute, National Institutes of Health, 
National Institute of Allergy and Infectious Diseases, Regeneron, 
Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of 
Research, and The Wistar Institute. For more information, visit www.inovio.com.

                                  * * * *

This press release contains certain forward-looking statements relating to our 
business, including our plans to develop DNA medicines, our expectations 
regarding our research and development programs, as well as commercialization 
activities, including the planned initiation and conduct of clinical trials, 
the availability and timing of data from those trials and our commercialization 
strategy and tactics. Actual events or results may differ from the expectations 
set forth herein as a result of a number of factors, including uncertainties 
inherent in pre-clinical studies, clinical trials, product development programs 
and commercialization activities and outcomes, the availability of funding to 
support continuing research and studies in an effort to prove safety and 
efficacy of electroporation technology as a delivery mechanism or develop 
viable DNA vaccines, our ability to support our pipeline of SynCon(R) active 
immunotherapy and vaccine products, the ability of our collaborators to attain 
development and commercial milestones for products we license and product sales 
that will enable us to receive future payments and royalties, the adequacy of 
our capital resources, the availability or potential availability of 
alternative therapies or treatments for the conditions targeted by us or our 
collaborators, including alternatives that may be more efficacious or cost 
effective than any therapy or treatment that we and our collaborators hope to 
develop, issues involving product liability, issues involving patents and 
whether they or licenses to them will provide us with meaningful protection 
from others using the covered technologies, whether such proprietary rights are 
enforceable or defensible or infringe or allegedly infringe on rights of others 
or can withstand claims of invalidity and whether we can finance or devote 
other significant resources that may be necessary to prosecute, protect or 
defend them, the level of corporate expenditures, assessments of our technology 
by potential corporate or other partners or collaborators, capital market 
conditions, the impact of government healthcare proposals and other factors set 
forth in our Annual Report on Form 10-K for the year ended December 31, 2018, 
our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and 
other filings we make from time to time with the Securities and Exchange 
Commission. There can be no assurance that any product candidate in our 
pipeline will be successfully developed, manufactured or commercialized, that 
final results of clinical trials will be supportive of regulatory approvals 
required to market products, or that any of the forward-looking information 
provided herein will be proven accurate. Forward-looking statements speak only 
as of the date of this release, and we undertake no obligation to update or 
revise these statements, except as may be required by law.

CONTACTS:
Investors:        Ben Matone, +1 484-362-0076, ben.matone@inovio.com 
Media:            Jeff Richardson, +1 267-440-4211, jrichardson@inovio.com


SOURCE: Inovio Pharmaceuticals, Inc.